An Open Label, Multicenter Study Investigating the Safety and Efficacy of Ofatumumab Therapy Versus Physicians' Choice in Patients With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukaemia (CLL)
Latest Information Update: 07 Sep 2023
At a glance
- Drugs Ofatumumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Registrational; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 16 Feb 2018 This trial has been discontinued in Great britan and Italy according to European Clinical Trials Database record.
- 28 Jun 2017 This trial has been Completed in Hungary (end date: 27 Apr 2017).
- 27 Jun 2017 This trial has been discontinued in Austria.